Innoviva, Inc. — Director's Dealing 2014

Jun 10, 2014

SEC Form 4/A — Form 4/A

Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2014-06-02

Reporting Person: PEPE PAUL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-06-02	Common Stock	A	7585	—	Acquired	7585	Direct
2014-06-02	Common Stock	A	7585	—	Acquired	15170	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-06-02	Stock Option (Right to Buy)	$23.0786	A	7585	Acquired	2024-06-01	Common Stock (7585)	Direct
2014-06-02	Stock Option (Right to Buy)	$23.0786	A	7585	Acquired	2024-06-01	Common Stock (7585)	Direct

Footnotes

F1: The number of shares was adjusted by a factor to account for the effect of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc. The factor was based on the 3-day post-spin volume weighted average price of Theravance, Inc, and Theravance Biopharma, Inc. and the stock dividend of one ordinary share of Theravance Biopharma, Inc. for every 3.5 shares of Theravance, Inc. common stock received by Theravance, Inc. stockholders as of the record date for the spin-off.

F2: This option may be exercised and shall be vested as to 1/24th of the shares subject to this option when optionee completes each continuous month of service following the grant date.

F3: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the Company's stockholders provided the optionee remains in continuous service on such date.